A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.
Humans
Stomach Neoplasms
/ surgery
Male
Female
Tegafur
/ administration & dosage
Middle Aged
Oxaliplatin
/ administration & dosage
Retrospective Studies
Gastrectomy
/ methods
Drug Combinations
Oxonic Acid
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Aged
Chemotherapy, Adjuvant
/ methods
Albumin-Bound Paclitaxel
/ administration & dosage
Adult
Disease-Free Survival
Paclitaxel
/ administration & dosage
Albumins
/ administration & dosage
Adjuvant chemotherapy
Albumin-bound paclitaxel
Disease free survival
Gastric cancer
S-1
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 07 2024
02 07 2024
Historique:
received:
26
04
2024
accepted:
24
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
Adjuvant oxaliplatin plus S-1 (SOX) chemotherapy for gastric cancer (GC) after D2 gastrectomy has been proven effective. There has yet to be a study that evaluates adjuvant nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus S-1. In this single-center, retrospective study, GC patients after D2 gastrectomy received either nab-paclitaxel plus S-1 (AS group) or SOX group were recruited between January 2018 and December 2020 in The First Affiliated Hospital of Zhejiang University. Intravenous nab-paclitaxel 120 mg/m
Identifiants
pubmed: 38956232
doi: 10.1038/s41598-024-65724-8
pii: 10.1038/s41598-024-65724-8
doi:
Substances chimiques
Tegafur
1548R74NSZ
Oxaliplatin
04ZR38536J
Drug Combinations
0
Oxonic Acid
5VT6420TIG
S 1 (combination)
150863-82-4
Albumin-Bound Paclitaxel
0
130-nm albumin-bound paclitaxel
0
Paclitaxel
P88XT4IS4D
Albumins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15150Subventions
Organisme : the Natural Science Foundation of Zhejiang Province
ID : LQ19H160042
Organisme : the Natural Science Foundation of Zhejiang Province
ID : LQ20H160028
Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Xia, C. et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin. Med. J. (Engl) 135, 584–590 (2022).
doi: 10.1097/CM9.0000000000002108
pubmed: 35143424
D’Angelica, M. et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann. Surg. 240, 808–816 (2004).
doi: 10.1097/01.sla.0000143245.28656.15
pubmed: 15492562
pmcid: 1356486
Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810–1820 (2007).
doi: 10.1056/NEJMoa072252
pubmed: 17978289
Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315–321 (2012).
doi: 10.1016/S0140-6736(11)61873-4
pubmed: 22226517
Kakeji, Y. et al. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer 25, 188–196 (2022).
doi: 10.1007/s10120-021-01224-2
pubmed: 34351555
Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22, 1081–1092 (2021).
doi: 10.1016/S1470-2045(21)00297-7
pubmed: 34252374
Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial. JAMA 330, 2064–2074 (2023).
doi: 10.1001/jama.2023.19918
pubmed: 38051328
pmcid: 10698618
Liu, T. et al. First-line nivolumab plus chemotherapy vs. chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. Int. J. Cancer 152, 749–760 (2023).
doi: 10.1002/ijc.34296
pubmed: 36121651
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).
doi: 10.1016/S0140-6736(21)00797-2
pubmed: 34102137
pmcid: 8436782
Shitara, K. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 25, 212 (2023).
doi: 10.1016/S1470-2045(23)00541-7
pubmed: 38134948
Terashima, M., Kang, Y.K., Kim, Y.-W., Boku, N., Chung, H.-C.-C., Chen, J.-S., Ji, J., Yeh, T.-S., Chen, L.-T., Ryu, M.-H., Kim, J.-G., Omori, T., Rha, S.-Y., Kim, T.-Y., Ryu, K.-W., Sakuramoto, S., Nishida, Y., Fukushima, N., Yamada, T. Sasako, M. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. In: 2023 ASCO Annual Meeting I: gastrointestinal cancer—gastroesophageal, pancreatic, and hepatobiliary, (abstr 4000), (2023)
Guven, D. C. et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 9, 1039121 (2022).
doi: 10.3389/fmolb.2022.1039121
pubmed: 36533070
pmcid: 9756377
Dall’Olio, F. G. et al. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A meta-analysis. Immunotherapy 13, 257–270 (2021).
doi: 10.2217/imt-2020-0179
pubmed: 33225800
Rizzo, A. et al. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: The MOUSEION-05 study. Cancer Immunol. Immunother. 72, 1381–1394 (2023).
doi: 10.1007/s00262-023-03366-x
pubmed: 36695827
pmcid: 10991194
Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).
doi: 10.1016/S0140-6736(18)32557-1
pubmed: 30982686
Al-Batran, S. E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 17, 1697–1708 (2016).
doi: 10.1016/S1470-2045(16)30531-9
pubmed: 27776843
Kang, Y. K. et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J. Clin. Oncol. 39, 2903–2913 (2021).
doi: 10.1200/JCO.20.02914
pubmed: 34133211
pmcid: 8425847
Giampieri, R. et al. Impact of signet-ring cell histology in the management of patients with non-metastatic gastric cancer: Results from a retrospective multicenter analysis comparing FLOT perioperative chemotherapy vs. surgery followed by adjuvant chemotherapy. Cancers (Basel) 15, 3342 (2023).
doi: 10.3390/cancers15133342
pubmed: 37444451
Tsuburaya, A. et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): A phase 3 factorial randomised controlled trial. Lancet Oncol. 15, 886–893 (2014).
doi: 10.1016/S1470-2045(14)70025-7
pubmed: 24954805
Su, L. et al. POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. Front Med. (Lausanne) 9, 861777 (2022).
doi: 10.3389/fmed.2022.861777
pubmed: 35983099
Shitara, K. et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): An open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 277–287 (2017).
doi: 10.1016/S2468-1253(16)30219-9
pubmed: 28404157
He, M. M. et al. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Sci. 109, 3575–3582 (2018).
doi: 10.1111/cas.13813
pubmed: 30281875
pmcid: 6215885
Cui, Y. et al. Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren’s diffuse-type gastric cancer after D2 resection (NORDICA study). Cancer Med. 12, 1114–1121 (2023).
doi: 10.1002/cam4.4966
pubmed: 35751496
Cheng, X. et al. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: A phase III multicenter, open-label, randomized controlled clinical trial protocol. BMC Cancer 21, 56 (2021).
doi: 10.1186/s12885-020-07772-7
pubmed: 33435909
pmcid: 7802165
Cheng, X. et al. The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: A real-world study. Gastric Cancer 22, 587–597 (2019).
doi: 10.1007/s10120-018-0895-x
pubmed: 30426294
Sasaki, Y. et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 105, 812–817 (2014).
doi: 10.1111/cas.12419
pubmed: 24716542
pmcid: 4317911
Ma, J. et al. Analysis of the efficacy and safety of paclitaxel (albumin-bound) combined with S-1 and oxaliplatin combined with S-1 in the first-line treatment of advanced gastric cancer: A cohort study. J. Gastrointest. Oncol. 13, 630–636 (2022).
doi: 10.21037/jgo-22-279
pubmed: 35557586
pmcid: 9086041